• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胰高血糖素样肽-1对糖尿病认知功能的影响及机制

Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus.

作者信息

Dou Xiaoke, Zhao Lei, Li Jing, Jiang Yaqiu

机构信息

Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, China.

Department of Gerontology, The First Hospital of China Medical University, Shenyang, China.

出版信息

Front Neurosci. 2025 Mar 18;19:1537898. doi: 10.3389/fnins.2025.1537898. eCollection 2025.

DOI:10.3389/fnins.2025.1537898
PMID:40171533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959055/
Abstract

BACKGROUND

Diabetes mellitus (DM) is a metabolic disorder associated with cognitive impairment. Glucagon-like peptide-1 (GLP-1) and its receptor (GLP-1R) have shown neuroprotective effects.

SCOPE OF REVIEW

This review explores the impact of DM on cognitive function. Diabetes-related cognitive impairment is divided into three stages: diabetes-associated cognitive decrements, mild cognitive impairment (MCI), and dementia. GLP-1R agonists (GLP-1RAs) have many functions, such as neuroprotection, inhibiting infection, and metabolic regulation, and show good application prospects in improving cognitive function. The mechanisms of GLP-1RAs neuroprotection may be interconnected, warranting further investigation. Understanding these mechanisms could lead to targeted treatments for diabetes-related cognitive dysfunction.

MAJOR CONCLUSIONS

Therefore, this paper reviewed the regulatory effects of GLP-1 on cognitive dysfunction and its possible mechanism. Further research is required to fully explore the potential of GLP-1 and its analogs in this context.

摘要

背景

糖尿病（DM）是一种与认知障碍相关的代谢紊乱疾病。胰高血糖素样肽-1（GLP-1）及其受体（GLP-1R）已显示出神经保护作用。

综述范围

本综述探讨糖尿病对认知功能的影响。糖尿病相关的认知障碍分为三个阶段：糖尿病相关的认知功能减退、轻度认知障碍（MCI）和痴呆。GLP-1受体激动剂（GLP-1RAs）具有多种功能，如神经保护、抑制感染和代谢调节，在改善认知功能方面显示出良好的应用前景。GLP-1RAs神经保护的机制可能相互关联，值得进一步研究。了解这些机制可能会为糖尿病相关的认知功能障碍带来针对性的治疗方法。

主要结论

因此，本文综述了GLP-1对认知功能障碍的调节作用及其可能机制。在这方面，需要进一步研究以充分探索GLP-1及其类似物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/11959055/798d39a4e33e/fnins-19-1537898-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/11959055/cd4b7e72672e/fnins-19-1537898-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/11959055/798d39a4e33e/fnins-19-1537898-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/11959055/cd4b7e72672e/fnins-19-1537898-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/11959055/798d39a4e33e/fnins-19-1537898-g002.jpg

相似文献

1
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus.胰高血糖素样肽-1对糖尿病认知功能的影响及机制
Front Neurosci. 2025 Mar 18;19:1537898. doi: 10.3389/fnins.2025.1537898. eCollection 2025.
2
Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.胰高血糖素样肽-1 受体激动剂在糖尿病认知功能下降和痴呆治疗中的潜在作用。
Int J Mol Sci. 2023 Jul 11;24(14):11301. doi: 10.3390/ijms241411301.
3
Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.胰高血糖素样肽-1 受体激动剂治疗慢性肾脏病伴 2 型糖尿病患者的疗效及其对肾脏的影响评价。
J Diabetes. 2019 Dec;11(12):938-948. doi: 10.1111/1753-0407.12969. Epub 2019 Aug 14.
4
Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.糖尿病大鼠急性和慢性脑损伤中的小胶质细胞参与：GLP-1RA 和 SGLT-2i 的影响。
Front Biosci (Landmark Ed). 2024 Jul 24;29(7):265. doi: 10.31083/j.fbl2907265.
5
Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?心境障碍中的认知功能障碍和代谢共病：胰高血糖素样肽 1 受体激动剂的再利用机会？
Neuropharmacology. 2018 Jul 1;136(Pt B):335-342. doi: 10.1016/j.neuropharm.2018.01.048. Epub 2018 Feb 23.
6
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.胰高血糖素样肽-1：聚焦神经退行性疾病
Front Neurosci. 2019 Oct 18;13:1112. doi: 10.3389/fnins.2019.01112. eCollection 2019.
7
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.GLP-1 受体激动剂：超越其胰腺作用。
Front Endocrinol (Lausanne). 2021 Aug 23;12:721135. doi: 10.3389/fendo.2021.721135. eCollection 2021.
8
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.胰高糖素样肽-1受体激动剂治疗2型糖尿病的研究进展
Front Pharmacol. 2025 Jan 20;15:1483792. doi: 10.3389/fphar.2024.1483792. eCollection 2024.
9
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment.胰高血糖素样肽-1受体激动剂对骨代谢的影响及其在骨质疏松症治疗中的可能机制
Front Pharmacol. 2021 Jun 14;12:697442. doi: 10.3389/fphar.2021.697442. eCollection 2021.
10
The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).胰高血糖素样肽-1受体（GLP-1R）激动剂在增强内皮功能中的作用：改善射血分数保留的心力衰竭（HFpEF）的潜在途径。
Cardiovasc Diabetol. 2025 Feb 7;24(1):70. doi: 10.1186/s12933-025-02607-w.

引用本文的文献

1
The impact of type 2 diabetes on aging: multidimensional approaches to preserve cognitive health.2型糖尿病对衰老的影响：维护认知健康的多维度方法。
Acta Diabetol. 2025 Sep 2. doi: 10.1007/s00592-025-02583-3.

本文引用的文献

1
Impaired brain glucose metabolism in glucagon-like peptide-1 receptor knockout mice.胰高血糖素样肽-1 受体敲除小鼠脑葡萄糖代谢受损。
Nutr Diabetes. 2024 Oct 10;14(1):86. doi: 10.1038/s41387-024-00343-w.
2
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.GLP-1 类药物治疗 2 型糖尿病和肥胖症的疗效和安全性。
Diabetes Care. 2024 Nov 1;47(11):1873-1888. doi: 10.2337/dci24-0003.
3
Trial of Lixisenatide in Early Parkinson's Disease.利西拉肽治疗早期帕金森病的试验。
N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323.
4
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.长效艾塞那肽不能预防轻度认知障碍的认知能力下降：一项概念验证临床试验。
J Endocrinol Invest. 2024 Sep;47(9):2339-2349. doi: 10.1007/s40618-024-02320-7. Epub 2024 Apr 2.
5
Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.GLP-1 受体激动剂相关的精神不良事件：基于 FDA 不良事件报告系统数据库的真实世界药物警戒研究。
Front Endocrinol (Lausanne). 2024 Feb 6;15:1330936. doi: 10.3389/fendo.2024.1330936. eCollection 2024.
6
Tirzepatide prevents neurodegeneration through multiple molecular pathways.替尔泊肽通过多种分子途径预防神经退行性变。
J Transl Med. 2024 Jan 29;22(1):114. doi: 10.1186/s12967-024-04927-z.
7
Associations of socioeconomic status and healthy lifestyle with incident early-onset and late-onset dementia: a prospective cohort study.社会经济地位和健康生活方式与早发性和晚发性痴呆发病的相关性：一项前瞻性队列研究。
Lancet Healthy Longev. 2023 Dec;4(12):e693-e702. doi: 10.1016/S2666-7568(23)00211-8.
8
Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway.司美格鲁肽通过GLP-1R/SIRT1/GLUT4途径改善阿尔茨海默病3xTg小鼠模型的认知和葡萄糖代谢功能障碍。
Neuropharmacology. 2023 Dec 1;240:109716. doi: 10.1016/j.neuropharm.2023.109716. Epub 2023 Sep 18.
9
Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.胰高血糖素样肽-1 受体激动剂在糖尿病认知功能下降和痴呆治疗中的潜在作用。
Int J Mol Sci. 2023 Jul 11;24(14):11301. doi: 10.3390/ijms241411301.
10
Impaired lipophagy induced-microglial lipid droplets accumulation contributes to the buildup of TREM1 in diabetes-associated cognitive impairment.受损的脂噬诱导小胶质细胞脂滴积累导致糖尿病相关认知障碍中 TREM1 的积累。
Autophagy. 2023 Oct;19(10):2639-2656. doi: 10.1080/15548627.2023.2213984. Epub 2023 May 19.